MMM:NYSE3M Company Analysis
Data as of 2026-03-10 - not real-time
$151.63
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
3M (MMM) is trading at $151.63, well below its 20‑day SMA of $164.94 and 50‑day SMA of $163.29, indicating short‑term weakness, but the RSI of 32.6 suggests the stock is oversold and could be poised for a bounce. Technical momentum remains mixed: the MACD histogram is negative and the signal is bearish, yet the computed trend direction is bullish and volume is increasing, supporting a potential near‑term rebound toward the $147.72 support level. Fundamentally, the company delivered an earnings beat in Q4 2025 with EPS of $1.83 versus expectations of $1.80, and the board has just declared a quarterly dividend of $3.12, yielding 2.03% with a payout ratio under 50%, indicating dividend sustainability.
However, valuation metrics raise caution: the DCF‑derived fair value of $26.22 is far below the current price, implying the stock is considerably overvalued (over 17% upside/downside misalignment). The debt‑to‑equity ratio of 276.6× and ongoing PFAS litigation add regulatory and balance‑sheet risk, while the sector’s industrial conglomerate exposure brings medium sector risk. Investors should weigh the solid cash flow and dividend against the high valuation, debt load, and regulatory headwinds when deciding on positioning.
However, valuation metrics raise caution: the DCF‑derived fair value of $26.22 is far below the current price, implying the stock is considerably overvalued (over 17% upside/downside misalignment). The debt‑to‑equity ratio of 276.6× and ongoing PFAS litigation add regulatory and balance‑sheet risk, while the sector’s industrial conglomerate exposure brings medium sector risk. Investors should weigh the solid cash flow and dividend against the high valuation, debt load, and regulatory headwinds when deciding on positioning.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Oversold RSI indicating potential rebound
- Recent earnings beat and dividend declaration
- Increasing volume supporting short‑term upside
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- Significant overvaluation relative to DCF fair value
- Strong cash flow and sustainable dividend yield
- Elevated debt levels and pending regulatory issues
Long Term
> 3 yearsCautious
Model confidence: 5/10
Key Factors
- Persistently high valuation without commensurate growth
- High debt‑to‑equity ratio and PFAS litigation risk
- Potential for continued regulatory and sector headwinds
Key Metrics & Analysis
Financial Health
Revenue Growth2.00%
Profit Margin13.03%
P/E Ratio25.6
ROE75.50%
ROA7.58%
Debt/Equity276.64
P/B Ratio17.1
Op. Cash Flow$2.3B
Free Cash Flow$1.3B
Industry P/E29.5
Technical Analysis
TrendBullish
RSI32.6
Support$147.72
Resistance$177.41
MA 20$164.94
MA 50$163.29
MA 200$158.33
MACDBearish
VolumeIncreasing
Fear & Greed Index75.89
Valuation
Fair Value$26.22
Target Price$178.73
Upside/Downside17.87%
GradeOvervalued
TypeValue
Dividend Yield2.03%
Risk Assessment
Beta1.08
Volatility30.17%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.